HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment

This item is licensed under: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

Files in This Item:
58_2077-18.pdf197.7 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/74043

Title: The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment
Authors: Suda, Goki Browse this author →KAKEN DB
Nakai, Masato Browse this author
Sho, Takuya Browse this author
Kimura, Megumi Browse this author
Shimazaki, Tomoe Browse this author
Maehara, Osamu Browse this author
Shigesawa, Taku Browse this author
Suzuki, Kazuharu Browse this author
Nakamura, Akihisa Browse this author
Ohara, Masatsugu Browse this author
Umemura, Machiko Browse this author
Kawagishi, Naoki Browse this author
Baba, Masaru Browse this author
Natsuizaka, Mitsuteru Browse this author →KAKEN DB
Morikawa, Kenichi Browse this author
Ogawa, Koji Browse this author →KAKEN DB
Sakamoto, Naoya Browse this author →KAKEN DB
Keywords: HCV
retreatment
glecaprevir
pibrentasvir
hemodialysis
Issue Date: 1-Apr-2019
Publisher: 日本内科学会
Journal Title: Internal medicine
Volume: 58
Issue: 7
Start Page: 943
End Page: 947
Publisher DOI: 10.2169/internalmedicine.2077-18
PMID: 30568153
Abstract: Clinical trials and real-world data have proven that hepatitis C virus (HCV) in most infected patients can be eradicated by direct-acting antivirals (DAAs). However, the proper retreatment regimen for hemodialysis patients with HCV infection who have previously failed to respond to DAAs has not been clarified. We herein report, for the first time, the successful retreatment with glecaprevir and pibrentasvir, of three hemodialysis patients with genotype 1 or 2 HCV infection, who had previously failed to respond to combination therapy with an HCV-NA5A inhibitor (daclatasvir) and an HCV protease inhibitor (asunaprevir).
Rights: https://creativecommons.org/licenses/by-nc-nd/4.0/
Type: article
URI: http://hdl.handle.net/2115/74043
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 須田 剛生

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

Feedback - Hokkaido University